Developing
PM-208

Perfusion Medical is developing a game-changing drug for the treatment of hemorrhagic shock and other ischemic conditions. PM-208, a novel IV therapeutic designed to rapidly re-establish blood flow through tissue capillaries to resolve ischemia and protect vital organs, has been developed with $19 million in Department of Defense funding. More than a dozen published studies from leading research institutions show the potential for PM-208 to help millions of patients.

Read More
Fixes capillary flow in
trauma and ischemia
Potential for 3x survival
improvements
Treats hemorrhagic shock,
AKI, Cardiac Shock & more

Latest News

View All
How it works graphic

How It Works

The primary mechanism of action of the PM-208 IV solution in treating severe hypovolemic shock is to increase tissue perfusion to facilitate rapid transfer of oxygen into oxygen-starved tissues and organs. This is accomplished by reversing the metabolic cell and tissue swelling that occurs during shock, which leads to capillary compression and a no-reflow phenomenon.

Perfusion Medical Is Developing A Critical New Life Science Technology

See our Technology page to learn more about how PM-208 works and how it can potentially help patients.

See our Press page to see a list of some of the impressive scientific publications about PM-208's main component PEG-20k.

Read our blogs to learn more about the Perfusion Medical team and where we are in the development, regulatory and investment process.

Applications Across Military And Civilian Trauma Care

The development of PM-208 at Virginia Commonwealth University was funded with more than $10 million from the US Army. As a result of that investment, the potential of PM-208 spans military and civilian medical care, with promising applications in trauma response and austere environments where access to advanced medical care is limited.

Publications View All

Oncotic Agent(s) Coming to the Rescue of “Drowning” Cells?

In this issue of the Journal of Pharmacology and Experimental Therapeutics, Liebrecht and colleagues (2023) offer the readership insights into an overarching mechanism of microvascular injury and a novel agent to curtail it. Mangino and colleagues have focused on a highly relevant mechanism of cell death due to cell swelling as a consequence of the loss of cellular ATP and the effectiveness of PEG-20k to prevent/alleviate such adverse outcomes (Liebrecht et al., 2023).

Read More
Publications View All

Superior Survival Outcomes of a Polyethylene Glycol-20k Based Resuscitation Solution

Annals of Surgery - Superior early and 24-hour outcomes were observed with PEG-20k LVR compared to WB and Hextend in a preclinical porcine model of lethal HS, despite decreased OCC from substantial volume-expansion

Read More
Publications View All

Effects of Polyethylene Glycol‐20k on Coronary Perfusion Pressure and Postresuscitation Myocardial.

Journal of the American Heart Association - Aortic infusion of PEG‐20k during cardiopulmonary resuscitation increases coronary perfusion pressure to the same extent as epinephrine, improves postresuscitation myocardial and cerebral function, and increases duration of survival in a rat model of cardiac arrest.

Read More